Introduction
The introduction of the Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) in the first-line treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) revolutionized patient outcome. Given the excellent hematologic and cytogenetic response rates that can be obtained in the chronic phase of the disease, 1 the goal of CML therapy has moved to the achievement of Major Molecular Response (MMR; defined as 3-log reduction in Bcr-Abl transcript level from a standardized baseline value) 2 and possibly of Complete Molecular Response (CMR; defined as at least 4-log reduction corresponding to undetectable Bcr-Abl transcript by real-time reverse transcription polymerase chain reaction), 2 which might represent an 'operational cure' as well as a pre-requisite for IM discontinuation. 3 Research in CML has since focused on finding biological predictors of response allowing for treatment optimization. It is well recognized that interpatient variability in drug response reflects the systemic levels or intracellular concentrations of the drug, known to be associated with the pharmacokinetics (absorption, distribution, and metabolism) of the drug itself. 4 IM is metabolized by the cytochrome-P450 -mostly CYP3A4 and 3A5
isoforms. 5 IM active uptake into cells is known to be mediated mainly by the hOCT1 transporter (encoded by the SLC22A1 gene), 6-7 whereas its efflux is mediated by the ABC transporters, in particular ABCB1 (also known as MDR1) and, to a lesser extent, ABCG2. 6, [8] [9] [10] Besides these, other transporters may be important in IM absorption, distribution, and elimination, including the families of organic cation transporters (OCTs) and organic anion transporters (OATs). In particular, a recent study by Hu et al., 11 identified IM as a substrate of OATP1A2 (encoded by SLCO1A2), whereas the involvement of members of the OCTN family as IM transporters is still uncertain.
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Interpatient variability in IM metabolism/transport is substantial and thus far unexplained. A possibility is that genetic polymorphisms in genes encoding IM metabolizing enzymes and transporters may influence the extent to which IM is delivered to target cells. Accordingly, genetic polymorphisms of the candidate genes CYP3A4/3A5, MDR1, ABCG2, OATP1A2, OCTN1 (encoded by SLC22A4) and hOCT1 could affect expression of corresponding proteins and thus may predict differences in IM response. To explore this hypothesis, we have selected a panel of polymorphisms in these genes and genotyped 189 newly diagnosed CML patients treated with IM in the framework of the TOPS (Tyrosine kinase OPtimization and Selectivity) phase III trial.
12

Design and Methods
Study population.
A total of 189 CML patients receiving IM were retrospectively enrolled in this pharmacogenetic study. These patients represented a subset of the TOPS trial -a randomized phase III study of IM 400 mg/d vs IM 800 mg/d in newly diagnosed and previously untreated CML patients in chronic phase. 12 Their selection was based exclusively on availability of a written informed consent for correlative sub-studies, according to the Helsinki Declaration and later Amendments, and sufficient amount of archived material. The study was approved by all local ethical committees. Patient characteristics and treatment protocol have been described elsewhere; 12 Table 1 summarizes selected demographic characteristics of our study population.
Evaluation of IM response.
Molecular response (MR) was classified based on BCR-ABL to control gene transcript ratios, expressed on the International Scale. 13 MMR and CMR were defined as ratios ≤ 0.1% and ≤ 0.0032%, respectively. Cytogenetic response (CgR) based on bone marrow assessment was classified as complete (CCgR; 0% Ph+ cells), partial (PCgR; > 0 to 35% 
Genotyping analysis.
DNA was extracted from cryopreserved white blood cells using conventional methods.
Characteristics of the studied polymorphisms (one insertion/deletion and 19 single nucleotide polymorphisms, from now on all referred as SNPs in the text) are reported in Supplemental Table S1 . Genotypes were determined by polymerase chain reaction (PCR)-based assays (restriction fragment length polymorphism and/or real-time) according to published methods, [14] [15] [16] [17] [18] [19] [20] or as recommended by manufacturer (Supplemental Table S1 ).
Positive and negative controls were included in each reaction as quality control. In addition, accuracy of genotyping was confirmed by repetition of 100% of the samples. The replicates were 100% concordant.
Statistical analysis.
Genotypes distribution, overall and by race, was tested for Hardy-Weinberg Equilibrium (HWE) with exact tests. 21 The association of individual SNPs with MMR, CMR, MCgR, and Inc., Cary, NC, USA).
The primary purpose of this study was to evaluate the effect of individual SNPs on response to IM therapy. As an exploratory analysis, we also examined simple summary measures of functionally related (uptake and efflux) SNPs. These were defined as the number of alleles, across the genes of interest, hypothesized or found in this study to be associated with favorable response. According to in vitro studies reported in the literature, we hypothesized a favorable response in the presence of hOCT1 rs4646277, rs4646278, and rs2282143, MDR1 rs1128503 (also known as C1236T), rs60023214 (also known as C3435T), rs1128501, and rs10245483 and OATP1A2 rs11568563 major alleles and ABCG2 rs2231137 and rs2231142 variant alleles. 21 For the remaining SNPs, no functional knowledge was available and the major allele was thus hypothesized to be associated with favorable response unless the present study suggested a different relationship.
Results
Genotype distribution
Genotype distributions of the 20 candidate SNPs are summarized in Supplemental Table   S2a -c. Five SNPs (hOCT1: rs4646277, rs4646278; MDR1: rs1128501; Cyp3A4: rs28371759 and Cyp3A5: rs28365083) were homozygous for the major allele for all patients and were excluded from the analyses. The comparison of genotype frequencies according to the patients' demographic characteristics revealed differences between Asian and Caucasian subgroups (Supplemental Table S2a Caucasian group showed deviation from the HWE.
Treatment outcome of IM therapy
Treatment outcomes for all patients and restricted to Caucasians are presented in Figure   1 . With a median total follow up time of 29 months among the entire study population, the 12-month post-randomization cumulative incidence of MMR, CMR, MCgR and CCgR was 67% (95% CI, 60%-73%), 9% (5%-14%), 82% (75%-87%), and 76% (70%-83%), respectively. Response rates in the Caucasian subgroup were similar. hazard models and evaluated with likelihood ratio tests are presented in Table 2 .
As far as MR was concerned, presence of the C allele in OCTN1 (rs1050152) had a favorable impact on MMR achievement (p=0.03). Nearly significant associations were observed in presence of MDR1 A (rs3213619) and MDR1 C (rs60023214) alleles with achievement of CMR (p=0.07 and p=0.06 respectively). With respect to the summary measures, combination of SNPs in the hOCT1 gene (see Supplemental Table S4 for combination design and distribution in the study population) was significantly correlated with MMR (p=0.03). The same combination had a weak effect on CMR achievement (p=0.08). When considering summary measures of uptake (see Supplemental Table S5 for combination design and distribution in the study population) and efflux, only the former was associated with both MMR and CMR (p=0.004 and p=0.01, respectively).
As far as CgR was concerned, hOCT1 C (rs2282143) was significantly associated with MCgR (p=0.05); nearly significant associations were observed in presence of MDR1 A (rs3213619) and OCTN1 C (rs1050152) alleles with achievement of MCgR (p=0.06 for both).
We also carried out analyses limited to Caucasian patients, our most representative sample set. All the results are presented in Supplemental Table S6 , while the most relevant ones are grouped in Table 3 . The analyses yielded results similar to those observed in the overall population. In particular, the presence of OCTN1 C (rs1050152) allele had a significantly favorable impact on achievement of MMR and a weak effect on CMR (p=0.03 and p=0.07, respectively). Combination of SNPs in hOCT1 (Supplemental Plots of the estimated fraction of patients achieving response by time since treatment initiation based on the Kaplan-Meier method were analysed in the overall population and separately for Caucasians. Presence of the minor allele in OCTN1 (TT rs1050152), was associated with decreased rate of MMR in the overall population and Caucasians (p=0.028
and p=0.027, respectively; Figure 2 ). Results were similar for CMR, and in general the curves separate at later times compared to MMR ( Figure 2) . Similarly, the combination of favorable alleles in the genes involved in IM uptake was associated with increased rates of both MMR and CMR (p=0.004 and p=0.015, respectively in the overall population, and p=0.005 and p=0.009, respectively, in Caucasians). In addition, an increase in the number of favorable alleles in the hOCT1 gene was associated with an increased MMR rate (p=0.030 and p=0.043 in the overall population and Caucasians, respectively).
In addition to these results, the analyses in the Caucasian subgroup confirmed the influence of two additional SNPs on MR. The major allele in MDR1 (CC-rs60023214) was significantly associated with increased rate of CMR and had a weak effect on MMR (p=0.005 and p=0.081, respectively; Figure 3A ). The major allele in CYP3A4 (AA rs2740574) was associated with decreased rate of MMR (p=0.038; Figure 3B ).
As previously reported, the three MDR1 polymorphisms rs1129503 (C1236T), rs2032582
(G2677T/A), and rs60023214 (C3435T), were found to be in strong linkage disequilibrium (rs1129503 and rs2032582: D′=0.76; rs1129503 and rs60023214: D′=0.51; rs2032582 and rs60023214: D′=0.61; test for LD among the three markers p<0.0001). However none of the resulting haplotypes (see Supplemental Table S7 for haplotype frequencies) was associated with IM response.
Analogous analyses were performed for loss of MMR, MCgR, and CCgR. However, the loss of response rates were quite low and no suggestion of association could be detected.
Analyses were also performed for evidence of differences by drug dose (IM 400mg vs IM 800mg), but no statistically significant associations were observed.
Discussion
The spectrum of therapeutic options for CML patients has recently been enriched by second generation TKIs that are more potent and/or more selective than IM in Bcr-Abl inhibition. Nilotinib and dasatinib had already proven remarkable efficacy in IM-resistant cases 22,23 and phase II and III studies in newly diagnosed patients have reported even higher rates of responses, obtained earlier during therapy, than those achievable with imatinib. [24] [25] [26] [27] Paradoxically, the availability of multiple therapeutic options is not paralleled by the availability of biological predictors of outcome allowing to identify, at the time of diagnosis, those patients who are more likely to benefit from nilotinib or dasatinib rather than from IM -hence there is still a need for CML treatment optimization. To this purpose, a refined stratification of patients in terms of likelihood to achieve MMR, or even better CMR, would be the necessary starting point. Despite intensive research efforts, the Sokal score has been for years the only reliable factor for risk prediction at the time of diagnosis.
Only recently, pretherapy hOCT1 transporter activity has been demonstrated to correlate with MMR and to predict for long-term risk of resistance to imatinib.
28,29
In several pathologic conditions, pharmacogenetics has proven to be a potential source of biomarkers given the known influence of polymorphisms in key genes encoding drug transporters and metabolizing enzymes on intracellular drug delivery -hence effectiveness.
In CML, only three studies had so far explored this field, but they all suffered from the limitation of being conducted in heterogeneous populations including patients at different stages of disease, not all treated with IM first-line 30,31 and of limited sample size.
32,33
In the present study, we investigated a panel of polymorphisms that can be hypothesized to influence IM transport and metabolism in a large series of newly diagnosed, previously untreated CML patients receiving IM in the framework of the TOPS phase III trial. This is a worldwide trial that enrolled patients of different ethnic origin -which brings the benefit to search for common genetic traits of response. We found, using a multiple candidate gene-SNP approach, that there are genes in the IM metabolism and transport pathways that are associated with the degree of MR to IM therapy. Examining multiple candidate genes (20 SNPs in 7 genes associated with IM metabolism and transport) also allows the possibility to assess potential effects of gene-gene interactions.
In this study, a SNP combination in hOCT1 was significantly associated with MMR, regardless of ethnicity. This finding is biologically plausible, especially in light of the fact that all the studied variants are in the coding region and lead to an amino acid change, assigning a putative functional role to these SNPs. It has been demonstrated that hOCT1
activity is an important determinant of MR to IM in CML patients. 28,34 Therefore, it is reasonable to expect that a combination of SNPs may influence hOCT1 expression and/or activity, thus playing a role in the achievement of MMR. It remains an open question, whether hOCT1 genotypes determine the levels of hOCT1 mRNA transcript or alter the transporter activity/selectivity -thus further studies are warranted in order to elucidate the correlation of hOCT1 genotypes and activity. Another combination of SNPs, all nonsynonymous -in genes involved in IM uptake (hOCT1, OCTN1, OATP1A2) -was even more significantly associated with both MMR and CMR, regardless of ethnicity. This finding, also biologically plausible, remarks the importance of individual pharmacokinetic differences on the response to IM therapy. In particular, interindividual variation in IM uptake can be considered as a complex phenotypic trait, which can be most probably explained as a complex genotypic feature (i.e. one SNPs vs combination of SNPs).
However, little or no functional data are available in the literature for these SNPs; so we can only hypothesize an effect on IM pharmacokinetic based on the fact that they all correspond to an amino acid variation in the protein sequence. An interesting finding was that the OCTN1 rs1050152-C allele was significantly associated with MMR in both the overall population and Caucasians. As far as we are aware, none of the pharmacokinetic studies of IM has pointed out the involvement of the OCTN1 protein in IM transport;
however, direct or indirect implication of this transporter in IM uptake cannot be excluded.
It is also possible that this association occurred by chance -making a replication of this observation in an independent data set mandatory, as well as further in vitro studies assessing which role OCTN1 may play in IM cellular uptake.
Our analyses in the Caucasian population also ascribed a role in the achievement of CMR to an MDR1 polymorphism, confirming that this transporter may be a critical determinant of intracellular IM levels. Several pharmacogenetic association studies have focused on MDR1 variants. In particular the role of three variants: rs1128503, rs60023214, and rs2032582 -better known from published studies as C1236T, C3435T and G2677T/Ahas been extensively studied, with strikingly contrasting results. Dulucq et al. 30 were the first to report an association between MDR1 rs2032582 (TT), rs1128503 (TT/TA) and higher MMR rates. They also found that the haplotype rs1128503 C, rs2032582 G, amount. Another intriguing hypothesis is that CGP74588 can be subjected to a different transport process -which would be in line with the observation of higher cellular uptake of CGP74588 as compared to IM made by le Coutre et al. 44 Obviously no definitive explanation can be given and further studies on the pharmacokinetics of CGP74588 would be needed.
The development in this study of combinations of SNPs to assess response to IM therapy provides only a preliminary examination of the potential for creation of a panel of markers to drive treatment decisions. Creation of such a panel of markers will require larger sample sizes for development followed by testing in an independent set.
In conclusion, this study showed that in CML patients, genotyping should be taken into account in an attempt to further individualize treatment, with the aim of enhancing efficacy in terms of MMR and CMR achievement. On the basis of these findings, stratification of patients according to genotypes may be proposed for selection between IM and second generation TKIs, and represents an attractive opportunity for new clinical trials.
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(B) Cumulative incidence of patients achieving MMR according to CYP3A4 rs2740574 genotype.
Given that for rs2740574 the major allele is A and the minor allele is G, AA carriers had a significantly higher MMR rate with respect to AG carriers (no GG carriers were detected in our study population). 
